YolTech has received FDA approval for its investigational new drug (IND) application for YOLT-101 to treat HeFH.

In this article, GlobalData examines key reimbursement trends that reflect the current delays to patient access across the ...

The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.

Aytu BioPharma has signed an agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua in the US market for MDD.

Vividion Therapeutics has secured worldwide rights for developing and commercialising VVD-214, the Werner helicase (WRN) ...

Italy’s Axxam and Molecular Health have partnered to identify and validate new therapeutic targets in drug development.

The FDA has granted expanded access authorisation for ImmunityBio’s Cancer BioShield platform, anchored by Anktiva, to treat ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

A new NDA was submitted in January 2024, which the FDA did accept, and that was later converted into a priority review. An ...

MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and with other ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to ...